유럽 익막 약물 시장, 질병 유형(진행성 익막 및 위축성 익막), 단계(2단계, 3단계, 1단계, 4단계), 치료 (인공 눈물/국소 윤활제 및 스테로이드 안약), 제형( 안약 , 안연고, 기타), 구매 방식(처방전 및 일반 의약품(OTC)), 인구 유형(노인 및 성인), 최종 사용자(병원, 전문 병원, 재택 의료, 기타), 유통 채널(소매 약국, 병원 약국, 온라인 약국, 기타) - 업계 동향 및 2029년까지의 전망.
시장 분석 및 통찰력
익막은 눈꺼풀 틈새 안의 변연 결막에서 시작하여 각막으로 진행되는 흔한 안구 표면 병변입니다. 이는 "날개"를 의미하는 그리스어 pterygos에서 따온 이름입니다. 이 병변은 측두엽보다 비강 변연에서 더 자주 발생하며 특징적인 날개 모양이 있습니다. 자외선 노출은 익막의 발생과 밀접한 관련이 있습니다. 자외선 노출 병력이 있거나 적도에 더 가깝게 사는 사람은 발병률이 더 높습니다(야외 작업). 특정 연구에 따르면 남성이 여성보다 발병률이 다소 높은데, 이는 자외선 노출률이 더 높기 때문일 수 있습니다.
발적, 염증, 눈 모양 변화를 일으킬 수 있습니다. 난시를 일으킬 수 있으며, 이는 시력을 흐리게 만들 수 있습니다. 눈 앞부분을 덮는 희끄무레하거나 분홍빛 성장이 생길 수 있습니다. 한쪽 또는 양쪽 눈에 영향을 미칠 수 있습니다.
익막염은 전체 눈 검사를 통해 눈의 앞쪽 부분을 현미경으로 검사하여 진단하며, 눈의 흰자위에서 각막에 조직이 자라는 모습을 통해 진단합니다.
Data Bridge Market Research에 따르면, 글로벌 유럽 익막약 시장이 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 4.8%로 성장할 것으로 분석되었습니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014로 사용자 정의 가능) |
|
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
|
다루는 세그먼트 |
질병 유형(진행성 익막 및 위축성 익막), 단계(2단계, 3단계, 1단계, 4단계), 치료(인공 눈물/국소 윤활제 및 스테로이드 안약), 제형(안약, 안연고, 기타), 구매 방식(처방 및 일반의약품(OTC)), 인구 유형(노인 및 성인), 최종 사용자(병원, 전문 병원, 가정 의료, 기타), 유통 채널(소매 약국, 병원 약국, 온라인 약국, 기타) |
|
적용 국가 |
러시아, 스페인, 터키, 독일, 이탈리아, 영국, 프랑스, 헝가리, 오스트리아, 스위스, 네덜란드, 폴란드, 아일랜드, 노르웨이, 리투아니아, 유럽의 나머지 지역 |
|
시장 참여자 포함 |
Johnson & Johnson Services, Inc.(미국), Novartis AG(스위스), Akorn Operating Company LLC(미국), Bausch & Lomb Incorporated(캐나다), AbbVie Inc.(미국), Prestige Consumer Healthcare Inc.(미국), Théa Laboratories(프랑스), Wellona Pharma(인도), SAGER PHARMA(헝가리), Sylentis(스페인), Bayer AG(독일), Zydus Group, Amneal Pharmaceuticals LLC(인도), OASIS Medical(미국), Similasan Corporation(스위스), Alcon(스위스), Santen Pharmaceutical Co., Ltd.(일본) |
시장 정의
익막은 눈꺼풀 틈새 안의 변연 결막에서 시작하여 각막으로 진행되는 흔한 안구 표면 병변입니다. 이는 "날개"를 의미하는 그리스어 pterygos에서 따온 이름입니다. 이 병변은 측두엽보다 비강 변연에서 더 자주 발생하며 특징적인 날개 모양이 있습니다. 자외선 노출은 익막의 발생과 밀접한 관련이 있습니다. 자외선 노출 병력이 있거나 적도에 더 가깝게 사는 사람은 발병률이 더 높습니다(야외 작업). 특정 연구에 따르면 남성이 여성보다 발병률이 다소 높은데, 이는 단순히 자외선 노출률이 더 높기 때문일 수 있습니다.
익막염은 전체 눈 검사를 통해 눈의 앞쪽 부분을 현미경으로 검사하여 진단하며, 눈의 흰자위에서 각막에 조직이 자라는 모습을 통해 진단합니다.
유럽 익막약 시장 동향
이 섹션에서는 시장 동인, 이점, 기회, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
- 안과 질환의 발생률 및 유병률의 증가
2021년 국립의학도서관(국립생명공학정보센터)에 발표된 자료에 따르면 유병률은 지역마다 다르다. 적도에서 남북으로 37°를 지나는 카메론의 "익막대"에서 가장 많이 발견된다.
익막의 가장 흔한 원인에는 태양의 자외선(UV)에 장기간 노출되는 것(가장 흔한 원인)과 더운 건조한 날씨, 바람, 먼지로 인한 눈 자극이 있습니다. 긍정적인 요인은 이것이 글로벌 익막 약물 시장의 주요 원동력이라고 말합니다.
- 노령 인구의 증가
전 세계적으로 노령 인구가 증가함에 따라 심각한 안구 통증을 동반한 안과 질환의 유병률도 증가하고 있습니다. "The Association for Research in Vision and Ophthalmology"(ARVO)가 발표한 "2020년 실명 및 원거리 및 근거리 시력 장애의 세계적 유병률: Vision 2020 목표에 대한 진전과 미래 전망"에 따르면 4,190만 명이 실명한 것으로 추산됩니다.
인구가 증가함에 따라 의료 시스템에 대한 압박이 증가하고 있습니다. 익막을 포함한 안과 질환 문제를 치료하기 위한 치료 및 서비스에 대한 수요가 증가하고 있습니다. 따라서 노령 인구의 증가는 유럽 익막 약물 시장에 큰 기회입니다.
기회
-
눈 질환 부담을 줄이기 위한 프로그램 및 이니셔티브
국제 실명 예방 기구는 평판이 좋은 NGO 및 기업과 협력하여 눈 질환에 대한 인식을 높이고 부담을 줄이기 위해 여러 프로그램과 이니셔티브를 시작했습니다.
예를 들어,
-
국제 기관은 Brien Holden Vision Institute와 Essilor가 만든 Vision For Life 기금(실명 예방을 위한 기금, IAPB)이 공동으로 설립한 Children's Vision 및 이니셔티브를 지지합니다.
제약/도전
다양한 안과 질환의 유병률이 증가함에 따라 시기적절한 치료의 필요성도 커졌습니다. 그러나 안과 질환에 대한 치료와 적절한 약물은 그다지 저렴하지 않습니다. 최근 연구에 따르면 국소 스테로이드 가격은 지난 몇 년 동안 상승하고 있습니다. 프레드니솔론과 같은 일부 국소 안과 스테로이드는 약간 저렴하지만 다른 고급 약물과 눈약은 여전히 비쌉니다.
유럽 익막약 시장 보고서는 최근의 새로운 개발, 무역 규정, 수출입 분석, 생산 분석, 가치 사슬 최적화, 시장 점유율, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 전략적 시장 성장 분석, 시장 규모, 범주 시장 성장, 응용 분야 틈새 시장 및 지배력, 제품 승인, 제품 출시, 지리적 확장, 시장의 기술 혁신에 대한 분석 기회를 제공합니다. 익막약 시장에 대한 자세한 정보를 얻으려면 Data Bridge Market Research에 연락하여 분석가 브리핑을 받으세요. 저희 팀은 시장 성장을 달성하기 위한 정보에 입각한 시장 결정을 내리는 데 도움을 드립니다.
환자 역학 분석
안과 질환의 유병률은 전 세계적으로 화학 산업과 오염의 증가로 인해 급증하는 추세를 보이고 있습니다. 화학 화상과 플래시 화상은 눈 표면의 자극으로 인해 심각하고 심한 눈 통증을 유발합니다.
2021년 국립의학도서관(국립생명공학정보센터)에 발표된 자료에 따르면 유병률은 지역마다 다릅니다. 적도에서 남북으로 37°를 지나는 카메론의 "익막대"에서 가장 많이 발견됩니다. 익막대 유병률은 전 세계적으로 0.3~29%로 보고되었습니다.
유럽 익막약 시장은 또한 환자 분석, 예후 및 치료법에 대한 자세한 시장 분석을 제공합니다. 유병률, 발생률, 사망률 및 준수는 보고서에서 사용할 수 있는 일부 데이터 변수입니다. 시장 성장에 대한 역학의 직접 또는 간접 영향 분석을 분석하여 성장 기간 동안 시장을 예측하기 위한 보다 견고하고 코핫 다변량 통계 모델을 만듭니다.
코로나19 이후 유럽 익막약 시장에 미치는 영향
COVID-19는 시장에 부정적인 영향을 미쳤습니다. 팬데믹 동안의 봉쇄와 격리는 질병 관리와 약물 복용을 복잡하게 만듭니다. 일상적인 치료와 약물 투여를 위한 의료 시설에 대한 접근성 부족은 시장에 더 큰 영향을 미칠 것입니다.
최근 개발
2021년 4월, 알콘은 미국에서 Systane 수분 다중 투여형 방부제 무첨가 윤활 눈약을 출시한다고 발표했습니다. 이 제품은 수분 결핍성 건조증으로 고생하는 환자를 위한 새로운 옵션이며 눈의 자극과 건조함을 더욱 완화하는 보호제 역할을 합니다. 이를 통해 회사는 포트폴리오를 늘릴 수 있었습니다.
유럽 익막약 시장 범위
유럽 익막약 시장은 질병 유형, 단계, 치료, 제형, 구매 방식, 인구 유형, 최종 사용자 및 유통 채널을 기준으로 8개의 주요 세그먼트로 분류됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내리는 데 도움이 되는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.
질병 유형
- 진행성 익막
- 위축성 익막
유럽 익막증 약물 시장은 질병 유형에 따라 진행성 익막증과 위축성 익막증으로 구분됩니다.
단계
- 1단계
- 2단계
- 3단계
- 4단계
유럽 익막증 약물 시장은 단계별로 1단계, 2단계, 3단계, 4단계로 구분됩니다.
치료
- 인공눈물/국소 윤활제
- 스테로이드 눈약
유럽 익막증 약물 시장은 치료에 따라 인공눈물/국소 윤활제와 스테로이드 안약으로 구분됩니다.
공식화
- 눈약
- 눈 연고
- 기타
유럽 익막증 약물 시장은 제형에 따라 안약, 연고 및 기타로 구분됩니다.
구매 방식
- 처방
- 처방전 없이 구입 가능한(OTC)
구매 방식을 기준으로 유럽 익막약 시장은 처방약과 일반의약품(OTC)으로 구분됩니다.
인구 유형
- 노인
- 성인
유럽 익막증 약물 시장은 인구 유형에 따라 노인층과 성인층으로 구분됩니다.
최종 사용자
- 병원
- 전문 클리닉
- 홈 헬스케어
- 기타
유럽 익막증 약물 시장은 최종 사용자를 기준으로 병원, 전문 클리닉, 가정 건강 관리 및 기타로 구분됩니다.
유통 채널
- 소매 약국
- 병원 약국
- 온라인 약국
- 기타
유럽 익막증 약물 시장은 유통 채널을 기준으로 소매 약국, 병원 약국, 온라인 약국으로 구분됩니다.
유럽 익막약 시장 지역 분석/통찰력
Europe pterygium drug market is analyzed, and market size insights and trends are provided by country, disease type, stages, treatment, formulation, mode of purchase, population type, end-user, and distribution channel. as referenced above.
The countries covered in the Europe pterygium drug market report are Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Hungary, Austria, Switzerland, Netherlands, Poland, Ireland, Norway, Lithuania, Rest of Europe.
Europe pterygium drug market is expected to grow due to the increasing prevalence of ophthalmic disorders and rising awareness of treatment for eye diseases.
Russia is expected to dominate the Europe pterygium drug market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high population suffering from pterygium.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Pterygium Drug Market Share Analysis
Europe pterygium drug market competitive landscape provides details of the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, European presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the pterygium drug market.
Some of the major players operating in the global Europe pterygium drug market are Johnson & Johnson Services, Inc., Novartis AG, Akorn Operating Company LLC, Bausch & Lomb Incorporated, AbbVie Inc., Prestige Consumer Healthcare Inc., Théa Laboratories, Wellona Pharma, SAGER PHARMA, Sylentis, Bayer AG, Zydus Group, Amneal Pharmaceuticals LLC, OASIS Medical, Similasan Corporation, Alcon, and Santen Pharmaceutical Co., Ltd. among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning grids, Market Time Line Analysis, Market Overview and Guide, Company Positioning grids, Company Market Share Analysis, Standards of Measurement, Europe Vs Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PTERYGIUM DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASS SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EUROPE PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 EUROPE PTERYGIUM DRUG MARKET: REGULATIONS
7.1 REGULATION IN THE U.S.
7.2 REGULATION IN EUROPE:
7.3 REGULATIONS IN CHINA:
7.4 REGULATIONS IN INDIA:
7.5 RELEVANT ACTS FOR THIS FRAMEWORK:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS
8.1.2 RISE IN GERIATRIC POPULATION
8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES
8.2 RESTRAINTS
8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION
8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS
8.3 OPPORTUNITIES
8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES
8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS
9 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 PROGRESSIVE PTERYGIUM
9.3 ATROPHIC PTERYGIUM
10 EUROPE PTERYGIUM DRUG MARKET, BY STAGES
10.1 OVERVIEW
10.2 STAGE 2
10.3 STAGE 3
10.4 STAGE 1
10.5 STAGE 4
11 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS
11.2.1 DEMULCENT
11.2.2 EMOLLIENTS
11.3 STEROID EYE DROPS
11.3.1 KETONE STEROIDS
11.3.1.1 PREDNOSOLONE
11.3.1.2 DEXAMETHASONE
11.3.1.3 FLUROMETHOLONE
11.3.1.4 OTHERS
11.3.2 ESTER STEROID (LOTERPREDNOL)
12 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 EYE DROPS
12.2.1 EYE DROPS WITH PRESERVATIVES
12.2.2 PRESERVATIVE-FREE EYE DROPS
12.3 EYE OINTMENTS
12.4 OTHERS
13 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER (OTC)
14 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULTS
15 EUROPE PTERYGIUM DRUG MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.3 HOSPITAL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 EUROPE PTERYGIUM DRUG MARKET, BY REGION
17.1 EUROPE
17.1.1 RUSSIA
17.1.2 SPAIN
17.1.3 TURKEY
17.1.4 GERMANY
17.1.5 ITALY
17.1.6 U.K.
17.1.7 FRANCE
17.1.8 HUNGARY
17.1.9 AUSTRIA
17.1.10 SWITZERLAND
17.1.11 NETHERLANDS
17.1.12 POLAND
17.1.13 IRELAND
17.1.14 NORWAY
17.1.15 LITHUANIA
17.1.16 REST OF EUROPE
18 EUROPE PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILES
20.1 ALCON
20.1.1 COMPANY SNAPSHOT
20.1.2 RECENT FINANCIALS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ABBVIE INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 BAUSCH & LOMB INCORPORATED
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 JOHNSON & JOHNSON SERVICES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 NOVARTIS AG
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 SANTEN PHARMACEUTICAL CO., LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 RECENT FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 AKORN OPERATING COMPANY LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AMNEAL PHARMACEUTICALS LLC.
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 EYERIS VISIONCARE PVT. LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 MAYA BIOTECH PRIVATE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 OASIS MEDICAL
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 PRESTIGE CONSUMER HEALTHCARE INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 SAGER PHARMA
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 SIMILASAN CORPORATION
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 SPECTRA VISION CARE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 SYLENTIS
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 THÉA LABORATORIES
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 WELLONA PHARMA
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.2 ZYDUS GROUP
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 EUROPE PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PROGRESSIVE PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ATROPHIC PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PTERYGIUM DRUG MARKET , BY STAGES, 2020-2029 (USD MILLION)
TABLE 6 EUROPE STAGE 2 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE STAGE 3 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE STAGE 1 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE STAGE 4 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE EYE OINTMENTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE PRESCRIPTION IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OVER THE COUNTER (OTC) IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE GERIATRICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ADULTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 EUROPE HOSPITALS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE SPECIALTY CLINICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HOME HEALTHCARE IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE HOSPITAL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE ONLINE PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 38 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 40 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 41 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 EUROPE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 47 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 48 EUROPE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 RUSSIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 51 RUSSIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 52 RUSSIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 RUSSIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 RUSSIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 RUSSIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 RUSSIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 57 RUSSIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 RUSSIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 59 RUSSIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 RUSSIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 RUSSIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 SPAIN PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 63 SPAIN PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 64 SPAIN PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 SPAIN ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SPAIN STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 SPAIN KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 SPAIN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 69 SPAIN EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 70 SPAIN PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 71 SPAIN PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 72 SPAIN PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 SPAIN PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 74 TURKEY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 TURKEY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 76 TURKEY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 TURKEY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 TURKEY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 TURKEY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 TURKEY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 81 TURKEY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 82 TURKEY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 83 TURKEY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 84 TURKEY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 TURKEY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 86 GERMANY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 87 GERMANY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 88 GERMANY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 89 GERMANY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 GERMANY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 GERMANY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 93 GERMANY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 94 GERMANY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 95 GERMANY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 96 GERMANY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 97 GERMANY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 ITALY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 100 ITALY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 ITALY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ITALY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ITALY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ITALY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 105 ITALY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 106 ITALY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 107 ITALY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 ITALY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 ITALY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 U.K. PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 111 U.K. PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 112 U.K. PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 113 U.K. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 U.K. STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 U.K. KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 U.K. PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 117 U.K. EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 118 U.K. PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 119 U.K. PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 120 U.K. PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 U.K. PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 FRANCE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 123 FRANCE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 124 FRANCE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 FRANCE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 FRANCE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 FRANCE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 129 FRANCE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 130 FRANCE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 131 FRANCE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 132 FRANCE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 FRANCE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 HUNGARY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 135 HUNGARY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 136 HUNGARY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 137 HUNGARY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 HUNGARY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 HUNGARY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 HUNGARY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 141 HUNGARY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 142 HUNGARY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 143 HUNGARY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 144 HUNGARY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 145 HUNGARY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 146 AUSTRIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 147 AUSTRIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 148 AUSTRIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 AUSTRIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 AUSTRIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 AUSTRIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 AUSTRIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 153 AUSTRIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 154 AUSTRIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 155 AUSTRIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 156 AUSTRIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 AUSTRIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 SWITZERLAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 159 SWITZERLAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 160 SWITZERLAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 SWITZERLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 SWITZERLAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 SWITZERLAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 SWITZERLAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 169 SWITZERLAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 NETHERLANDS PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 171 NETHERLANDS PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 172 NETHERLANDS PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 173 NETHERLANDS ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 NETHERLANDS STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 NETHERLANDS KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 NETHERLANDS PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 177 NETHERLANDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 178 NETHERLANDS PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 179 NETHERLANDS PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 180 NETHERLANDS PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 181 NETHERLANDS PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 182 POLAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 183 POLAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 184 POLAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 185 POLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 POLAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 POLAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 POLAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 189 POLAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 190 POLAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 191 POLAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 192 POLAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 193 POLAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 194 IRELAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 195 IRELAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 196 IRELAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 197 IRELAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 IRELAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 IRELAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 IRELAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 201 IRELAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 202 IRELAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 203 IRELAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 204 IRELAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 IRELAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 NORWAY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 207 NORWAY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 208 NORWAY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 209 NORWAY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 NORWAY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 NORWAY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 NORWAY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 213 NORWAY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 214 NORWAY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 215 NORWAY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 216 NORWAY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 217 NORWAY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 218 LITHUANIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 219 LITHUANIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 220 LITHUANIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 221 LITHUANIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 LITHUANIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 LITHUANIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 LITHUANIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 225 LITHUANIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 226 LITHUANIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 227 LITHUANIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 228 LITHUANIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 229 LITHUANIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 230 REST OF EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 2 EUROPE PTERYGIUM DRUG MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PTERYGIUM DRUG MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PTERYGIUM DRUG MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PTERYGIUM DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PTERYGIUM DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PTERYGIUM DRUG MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE PTERYGIUM DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE PTERYGIUM DRUG MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC IS ANTICIPATED TO DOMINATE THE PTERYGIUM DRUG MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND RISE IN GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE EUROPE PTERYGIUM DRUG MARKET FROM 2022 TO 2029
FIGURE 13 PROGRESSIVE PTERYGIUM SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE PTERYGIUM DRUG MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PTERYGIUM DRUG MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2021
FIGURE 17 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, 2021
FIGURE 21 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, 2021
FIGURE 25 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, 2021
FIGURE 29 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2021
FIGURE 33 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 34 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 35 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 36 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2021
FIGURE 37 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 EUROPE PTERYGIUM DRUG MARKET: BY END USER, 2021
FIGURE 41 EUROPE PTERYGIUM DRUG MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 EUROPE PTERYGIUM DRUG MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 EUROPE PTERYGIUM DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 EUROPE PTERYGIUM DRUG MARKET: SNAPSHOT (2021)
FIGURE 49 EUROPE PTERYGIUM DRUG MARKET: BY COUNTRY (2021)
FIGURE 50 EUROPE PTERYGIUM DRUG MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 EUROPE PTERYGIUM DRUG MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 EUROPE PTERYGIUM DRUG MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
